Drugs · acquisition-cost intelligence
furosemide
· ingredient furosemide· FUROSEMIDE 100 mg/10mL; FUROSEMIDE 10 mg/mL; FUROSEMIDE 20 mg/2mL; FUROSEMIDE 40 mg/4mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.37859
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 10 weeks.
2025-07-232026-05-20
Same-ingredient options by acquisition cost
Other furosemide products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| UDSx Medicated System | $0.02961 | −$0.34900 |
| Lasix | $0.03173 | −$0.34690 |
| Furosemide | $0.09404 | −$0.28450 |
| furosemide | $0.34173 | −$0.03690 |
| furosemide | $0.41545 | +$0.03690 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.